SurvivorNet on MSN
For triple-negative breast cancer patients without immunotherapy options, FDA approval of Datroway brings hope by helping patients live longer
The FDA has approved Datroway (datopotamab deruxtecan) for adults with unresectable or metastatic triple‑negative breast ...
GlobalData on MSN
ASCO26: Abbott demonstrates MRD test benefit in TNBC recurrence
Abbott presented the data obtained from a prospective sub-study of the PARTNER trial at this year’s ASCO meeting in Chicago, ...
Izalontamab brengitecan extends overall survival among patients with metastatic TNBC, but it’s unclear how the ...
Iza-bren improved survival and delayed disease progression versus chemotherapy in previously treated metastatic ...
MedPage Today on MSN
Investigational ADC Ups Survival in Advanced Triple-Negative Breast Cancer
Izalontamab brengitecan more than doubled PFS compared with chemotherapy ...
Percheron Therapeutics Ltd (ASX:PER, OTC:PERCF) has unveiled new preclinical data suggesting its lead cancer therapy HMBD-002 ...
MedPage Today on MSN
New first-line option approved in triple-negative breast cancer
Datopotamab deruxtecan indicated for patients ineligible for immunotherapy ...
Iza-bren is a potentially first-in-class bispecific ADC designed to target both EGFR and HER3. It features high affinity for ...
The TROP2 battle in first-line triple-negative breast cancer has officially kicked off. | A three-way battle among TROP2 ADCs in first-line triple-negative breast cancer is forming as AstraZeneca and ...
The Food and Drug Administration (FDA) on May 22, 2026, approved Datroway (datopotamab deruxtecan-dlnk) for adult patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results